Stock Events

Stock Events

Bright Minds Biosciences 

$76.37
76
-$0.26-0.34% 16:13 Today

Statistics

Day High
76.55
Day Low
75.99
52W High
123.75
52W Low
38
Volume
124
Avg. Volume
-
Mkt Cap
749.35M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
-1.22
-0.81
-0.4
0.01
Expected EPS
-1.223016
Actual EPS
-0.173079

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-8.8MNet Income

Analyst Ratings

164.25Average Price Target
The highest estimate is 220.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DRUG. It's not an investment recommendation.
NVIDIA
14
NVDA
Apple
11
AAPL
Microsoft
11
MSFT
Meta Platforms
10
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap16.51B
Jazz Pharmaceuticals has a strong portfolio in neuroscience, including treatments for psychiatric disorders, overlapping with Bright Minds' focus.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.08B
Acadia Pharmaceuticals develops drugs for central nervous system disorders, directly competing with Bright Minds in the psychiatric and neurological treatment market.
Alkermes
ALKS
Mkt Cap8.11B
Alkermes focuses on central nervous system diseases, including schizophrenia and depression, competing in the same therapeutic areas as Bright Minds.
BridgeBio Pharma
BBIO
Mkt Cap15.93B
BridgeBio Pharma targets genetic diseases and precisely engineered drugs, some of which involve neurological conditions, making them a competitor.
Corbus Pharmaceuticals
CRBP
Mkt Cap200.76M
Corbus Pharmaceuticals works on treatments for inflammatory and fibrotic diseases with potential applications in neuropsychiatric disorders.
Neurocrine Biosciences
NBIX
Mkt Cap15.51B
Neurocrine Biosciences specializes in neurologic, psychiatric, and endocrine-related diseases, directly competing in Bright Minds' market.
PTC Therapeutics
PTCT
Mkt Cap5.83B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines, including treatments for neurological disorders, making them a competitor in the broader neuropharmaceutical field.

About

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Show more...
CEO
Ian McDonald
Employees
25
Country
Canada
ISIN
CA10919W4056

Listings

XNAS
US
DRUG
CN
CA
DRUG.CN
BOATS
BOATS
DRUG.BOATS

0 Comments

Share your thoughts

FAQ

What is Bright Minds Biosciences stock price today?▼
The current price of DRUG is $76.37 USD — it has decreased by -0.34% in the past 24 hours. Watch Bright Minds Biosciences stock price performance more closely on the chart.
What is Bright Minds Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Bright Minds Biosciences stocks are traded under the ticker DRUG.
Is Bright Minds Biosciences stock price growing?▼
DRUG stock has fallen by -3.18% compared to the previous week, the month change is a +5.77% rise, over the last year Bright Minds Biosciences has showed a +75.42% increase.
What is Bright Minds Biosciences market cap?▼
Today Bright Minds Biosciences has the market capitalization of 749.35M
When is the next Bright Minds Biosciences earnings date?▼
Bright Minds Biosciences is going to release the next earnings report on December 17, 2026.
What were Bright Minds Biosciences earnings last quarter?▼
DRUG earnings for the last quarter are -0.17 USD per share, whereas the estimation was -1.22 USD resulting in a +85.85% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bright Minds Biosciences revenue for the last year?▼
Bright Minds Biosciences revenue for the last year amounts to 0 USD.
What is Bright Minds Biosciences net income for the last year?▼
DRUG net income for the last year is -8.8M USD.
How many employees does Bright Minds Biosciences have?▼
As of August 27, 2026, the company has 25 employees.
In which sector is Bright Minds Biosciences located?▼
Bright Minds Biosciences operates in the Health & Wellness sector.
When did Bright Minds Biosciences complete a stock split?▼
The last stock split for Bright Minds Biosciences was on July 14, 2023 with a ratio of 1:5.
Where is Bright Minds Biosciences headquartered?▼
Bright Minds Biosciences is headquartered in New York, Canada.